07/19/2023
Several State AGs recently announced a multi-state settlement amounting to $102.5 million with Indivior Inc., the manufacturer of Suboxone, due to purported monopoly practices.
In 2002, Indivior Inc. received FDA approval for Suboxone and was given an exclusive seven-year period to market the drug. However, in 2010 - just a year after their exclusive rights to the Suboxone tablet expired and generic versions were ready to enter the market, the company transitioned from tablets to sublingual film, citing safety issues. The company eventually stopped selling tablets, obligating customers to purchase the pricier film version of the drug. A group of 41 state AGs took legal action against Indivior in 2016. They accused the company of blocking competition through a strategy known as "product-hopping." This practice involves drug manufacturers maintaining a monopoly on profitable drugs by slightly altering them to hinder generic competition without providing new therapeutic advantages to patients.
In 2019, Indivior’s former parent company, Reckitt Benckiser Group paid $1.4B to address potential criminal and civil liabilities stemming from a federal probe into the marketing practices of Suboxone. In 2020, Indivior Solutions, a subsidiary of Indivior Inc., was ordered to pay $600M and plead guilty to felony and misdemeanor charges connected with making false statements about Suboxone Film’s safety. Indivior Inc. is also the manufacturer of the new controversial overdose reversal medication Opvee.
Community Education Group - CEG